Life Technologies' Ion AmpliSeq™ Exome Certified Service Provider Program Adds European Members

GLASGOW, Scotland, Oct. 28, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announces four new members in Europe to its Ion AmpliSeq™ Exome Certified Service Provider program, an organization of some of the world's top service providers that sequence and analyze human exomes.  Using the Ion AmpliSeq™ Exome Kit, the Ion Proton™ Sequencer, and the Ion Reporter™ Software, service providers can sequence two exomes in a single run-going from DNA to results in just two days.

Until now, exome sequencing through a service provider has cost $1,000 or more, taken six to eight weeks and required as much as three micrograms of DNA. Exome sequencing with Ion AmpliSeq™ Exome Certified Service Providers requires just 50 ng of DNA and is competitively priced, making exome sequencing accessible to any researcher. This program eliminates the need to batch samples just to make the price of exome sequencing affordable.

The Ion AmpliSeq™ Exome Certified Service Provider program welcomes the following European institutions:

• La Plate-Forme Séquençage et Génomique, Institut Cochin, Paris, France
• Uppsala Genome Center, Uppsala University, Sweden
• CRIBI Genomics Group, University of Padua, Italy
• Biocant, Technology Transfer Association, Portugal

In addition to being faster and more affordable, the Ion AmpliSeq™ Exome Kit delivers the most uniform sequencing coverage in the industry*, with up to 98 percent of bases covered at 10-fold, and up to 95 percent of bases covered at 20-fold, for a single exome. 

"AmpliSeq exome sequencing using the  Ion Proton™ provides fast and accurate data to understand the genetic traits of several diseases," said Dr. Conceição Egas, Head of Genoinseq, the Next Gen Sequencing Unit of Biocant. "The simple and high throughput workflow of sample preparation, sequencing and data analysis perfectly suits our goal of delivering high quality results for our clients with cost-effective solutions."

Customers of the provider program have the ability to receive their data from Ion Reporter™ Software, which provides a list of mutations, including copy number variation, and associated annotations drawn from dozens of public databases within hours after a sequencing run. It also enables service labs to access their data through the web and rich filtering tools that help them focus on the most relevant variants.

"With such demand and leading institutions joining in North America, the program will soon expand globally," said Maneesh Jain, Vice President of Marketing, Product and Program Management at Life Technologies. "The service provider program model allows customer samples to be performed quickly and easily to fit any size research project."

The Ion AmpliSeq™ Exome Certified Service Provider program is part of the Ion Certified Service Provider program. To learn more, visit: lifetechnologies.com/ioncsp

The Ion AmpliSeq™ Exome Kit and Ion Proton™ Sequencer are For Research Use Only. Not for use in diagnostic procedures.

*For complete details on the performance of the Ion AmpliSeq™ Exome Kit and Ion Proton™ Sequencer, go to our web page at lifetechnologies.com/ionexome.

About Life Technologies 
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum—scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact:
David Robertson
+44 141 814 5889
david.robertson@lifetech.com